Think Surgical, Inc.
$103.4K 207 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Halozyme Inc
Halozyme Inc reported $103,295.09 across General Payments, Research, and Ownership to 326 physicians and teaching hospitals across 327 transactions.
- $103.3K Below-median payer
- All-tracks total
- 327 Above-median volume
- Transactions
- 326 Above-median reach
- Recipients
- −$226.6K
- General Payments vs PY2023
Halozyme Inc reported $103,295.09 across all CMS Open Payments tracks (General + Research + Ownership) to 326 physicians and teaching hospitals in Program Year 2024 - ranking #1176 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $55,967.09, averaging $316.86 per recipient.
How Halozyme Inc's $103.3K all-tracks total breaks down
Halozyme Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
11/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer halozyme-inc Halozyme Inc
$103.3K · #1176/1,925 · 0.0% industry · PY2024
- TOT $103.3K
- RANK #1176
- SHARE 0.0%
- TXN 327
- RCP 326
- CAT 3
- GEN $56.0K
- ΔGEN −$226.6K
- TOP1 75.3%
- PY 2024
Volume peers
Nearest volume peer: Think Surgical, Inc. ($103.4K)
Halozyme Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Halozyme Inc's CMS-reported General Payments decreased by $226.6K (−80.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: HALOZYME INCPY2023: HALOZYME INCPY2024: Halozyme Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $282,518.82
- PY2024
- $55,967.09
What the Data Shows for Halozyme Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Halozyme Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
21 transactions worth $44.8K make "Consulting Fee" the top general-payment category in the 3-category breakdown below, 80.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Halozyme Inc's 3-category general-payment breakdown at $44.8K, 80.0% of the reported total.
How Halozyme Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $44.8K | 21 | 80.0% |
| Food and Beverage | $6.1K | 297 | 10.9% |
| Travel and Lodging | $5.1K | 8 | 9.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $44,503.52 (79.5%) of $55,967.09 in this company's General Payments records across 183 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Halozyme Inc
The five named recipients with the highest reported General Payments from this company
- 1
Mahesh Krishnan
$42,124.52 across 15 reported transactions
- 2
Giancarlo Moscol
$610.00 across 1 reported transactions
- 3
Sherif M Badawy
$609.00 across 1 reported transactions
- 4
Laura Geraldino
$590.00 across 1 reported transactions
- 5
Michael Wechsler
$570.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Halozyme Inc ranks #1176 of 1,925 by total payments (bottom 39% by spend) but is notably more concentrated than that alone would suggest -- #283 of 1,838 by HHI (top 15% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Novo Nordisk US Research & Development, Inc. : $7.8K total payments, HHI 5774
- Spinevision SAS : $66.0K total payments, HHI 5765
- Cook Medical LLC : $2.8M total payments, HHI 5718
- Channel Medsystems, Inc. : $194.3K total payments, HHI 5715
- Adagio Medical, Inc. : $49.5K total payments, HHI 5713
- Radical Catheter Technologies, Inc. : $15.2K total payments, HHI 5702
- Halozyme Inc (this company) : $56.0K total payments, HHI 5678
- Laminate Medical Technologies inc. : $37.7K total payments, HHI 5660
- OrthoXel Designated Activity Company : $10.4K total payments, HHI 5646
- Biotest AG : $14.7K total payments, HHI 5643
- Atos Medical Inc : $110.5K total payments, HHI 5624
- Zerigo Health, Inc. : $7.5K total payments, HHI 5622
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Halozyme Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Halozyme Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Halozyme Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Actelion Pharmaceuticals, Ltd
$103.2K 55 recipients
Compare payment profiles
HMU Consumables, LLC
$103.7K 0 recipients
Compare payment profiles
OrthoPediatrics Canada ULC
$104.0K 5 recipients
Compare payment profiles
Astute Medical, Inc.
$104.6K 0 recipients
Compare payment profiles
Pylant Medical
$104.7K 1,589 recipients
Compare payment profiles
Put this to use
Halozyme Inc ranks #1176 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Halozyme Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.